8/5/2008

China-based Beike Biotechnology is using a promising but untested therapy involving induced pluripotent stem cells to treat hundreds of patients -- many from Western countries -- suffering from diseases deemed incurable, such as cerebral palsy and muscular dystrophy. The company's technology, which uses a combination of umbilical-cord cells and stem cells extracted from patients, "may someday create the conditions for effective clinical treatments and industrial scale production of iPS cells," a U.S. researcher said.

Full Story:
InformationWeek

Related Summaries